RxDoctor Payments Data

Vivek Sailam, MD

Cardiovascular Disease · Sewell, NJNPI 1386819589

Payments from drug & device makers

$28,432in general payments, 2019–2025

Across 737 payments — averaging $38.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$20K
  • Amgen$2K
  • Novartis$1K
  • Boston Scientific$748
  • Boehringer Ingelheim$535
  • Pfizer$535
  • plus $4K from 31 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$18,20064%
  • Food & beverage$9,90435%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,432 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$578,369
Medicare patients
1,817
Services billed
5,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban374$442,418
XareltoRivaroxaban124$156,390
Repatha SureclickEvolocumab104$109,861
EntrestoSacubitril/Valsartan72$102,331
Praluent PenAlirocumab28$25,618
FarxigaDapagliflozin Propanediol20$19,583
BrilintaTicagrelor14$17,113
Repatha PushtronexEvolocumab12$16,645
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid81$14,475
Nebivolol Hcl145$8,558
Icosapent Ethyl14$7,262
Metoprolol Succinate519$6,307
Atorvastatin Calcium480$5,900
Rosuvastatin Calcium252$4,279
Ranolazine ErRanolazine69$4,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$535$442,418374 claims
Johnson & JohnsonXarelto$19,635$156,390124 claims
NovartisEntresto$1,206$102,33172 claims
AstraZenecaFarxiga, Brilinta$227$36,69634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →